Investor, didn't TGD state @ AGM or the Q2 cc that Anavex had the 15 Rett participants identified. IMO, some of those 15 did not pass the PM/biomarkers criteria to be included. How many, who knows, but it obviously delayed the full enrollment PR that we are waiting to see.
I2014 Maybe I have this wrong, but as I understand it the trial with the 6 18 -45 year olds was to show that 2-73 is well tolerated by Rett patients. There was an efficacy component to the trial also.
Now that trial is close to over, if not over, they are recruiting the younger patients in the larger trial.
Market Data 
Markets 
